Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fast-acting Insulin Aspart in iLet Bionic Pancreas for T1D
NCT03816761Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Feb 2019
- Primary completion
- May 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of insulin aspart in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Novo Nordisk. Primary endpoints: Time in Low Interstitial Glucose (< 54 mg/dL) and Median Time in Low Interstitial Glucose (< 54 mg/dL). Started Feb 2019; status: completed.
02
Drugs
insulin aspart
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT03816761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03816761.